These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26212126)

  • 41. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
    Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
    Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synaptotagmin 3 deficiency in T cells impairs recycling of the chemokine receptor CXCR4 and thereby inhibits CXCL12 chemokine-induced migration.
    Masztalerz A; Zeelenberg IS; Wijnands YM; de Bruijn R; Drager AM; Janssen H; Roos E
    J Cell Sci; 2007 Jan; 120(Pt 2):219-28. PubMed ID: 17179206
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Am80 inhibits stromal cell-derived factor-1-induced chemotaxis in T-cell acute lymphoblastic leukemia cells.
    Matsumoto T; Jimi S; Hara S; Takamatsu Y; Suzumiya J; Tamura K
    Leuk Lymphoma; 2010 Mar; 51(3):507-14. PubMed ID: 20141446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential effects of IFN-beta1b on the proliferation of human vascular smooth muscle and endothelial cells.
    Mintzer RJ; Croze E; Rubanyi GM; Johns A
    J Interferon Cytokine Res; 1998 Nov; 18(11):939-45. PubMed ID: 9858315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis.
    Serrano-Pertierra E; Blanco-Gelaz MA; Oliva-Nacarino P; Martínez-Camblor P; Villafani J; López-Larrea C; Cernuda-Morollón E
    J Neuroimmunol; 2015 May; 282():39-44. PubMed ID: 25903727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
    Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
    J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.
    Kraus J; Bauer R; Chatzimanolis N; Engelhardt B; Tofighi J; Bregenzer T; Kuehne BS; Stolz E; Blaes F; Morgen K; Traupe H; Kaps M; Oschmann P
    J Neurol; 2004 Apr; 251(4):464-72. PubMed ID: 15083294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
    Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
    Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN-α in patients with relapsing-remitting multiple sclerosis.
    Deckx N; Willekens B; Wens I; Eijnde BO; Goossens H; Van Damme P; Berneman ZN; Cools N
    Innate Immun; 2016 May; 22(4):266-73. PubMed ID: 27036414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients.
    Weinstock-Guttman B; Hong J; Santos R; Tamaño-Blanco M; Badgett D; Patrick K; Baier M; Feichter J; Gallagher E; Garg N; Ramanathan M
    Mult Scler; 2006 Oct; 12(5):541-50. PubMed ID: 17086898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro.
    Bajetto A; Barbieri F; Pattarozzi A; Dorcaratto A; Porcile C; Ravetti JL; Zona G; Spaziante R; Schettini G; Florio T
    Neuro Oncol; 2007 Jan; 9(1):3-11. PubMed ID: 17108064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
    Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of endogenous IFN-β in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis.
    Tao Y; Zhang X; Chopra M; Kim MJ; Buch KR; Kong D; Jin J; Tang Y; Zhu H; Jewells V; Markovic-Plese S
    J Immunol; 2014 Jun; 192(12):5610-7. PubMed ID: 24850724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients.
    Giacomini E; Severa M; Rizzo F; Mechelli R; Annibali V; Ristori G; Riccieri V; Salvetti M; Coccia EM
    Eur J Immunol; 2013 Jul; 43(7):1963-72. PubMed ID: 23636665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
    Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis.
    Yushchenko M; Mäder M; Elitok E; Bitsch A; Dressel A; Tumani H; Bogumil T; Kitze B; Poser S; Weber F
    J Neurol; 2003 Oct; 250(10):1224-8. PubMed ID: 14586607
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
    Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
    J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tetramethylpyrazine (TMP), an Active Ingredient of Chinese Herb Medicine Chuanxiong, Attenuates the Degeneration of Trabecular Meshwork through SDF-1/CXCR4 Axis.
    Yu N; Zhang Z; Chen P; Zhong Y; Cai X; Hu H; Yang Y; Zhang J; Li K; Ge J; Yu K; Liu X; Zhuang J
    PLoS One; 2015; 10(8):e0133055. PubMed ID: 26275042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
    Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
    Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.